Literature DB >> 33580937

Successful combined treatment of Buschke-Lowenstein tumor in anal canal with electroresection, photodynamic therapy and topical 5% imiquimod.

Xiaobao Huang1, Mingna Liu1, Jiande Han1, Chunguang Ma1.   

Abstract

Entities:  

Year:  2021        PMID： 33580937     DOI： 10.4103/ijdvl.IJDVL_856_20

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN： 0378-6323            Impact factor:   2.545


× No keyword cloud information.
  5 in total

1.  Successful treatment of recurrent and refractory cervical condylomata acuminata with topical 5% imiquimod cream in five patients.

Authors:  C G Ma; M K Chen; S C Yang; S Bai; Q M Liao
Journal:  Int J STD AIDS       Date:  2010-07       Impact factor: 1.359

2.  Photodynamic therapy for the treatment of endoanal condylomata acuminata.

Authors:  Riccardo Gattai; Daniele Torchia; Camilla Salvini; Beatrice Magini; Claudio Comacchi; Alessio Cappuccini; Irene Ruffino; Pier Giacomo Calzavara Pinton; Pietro Cappugi
Journal:  Clin Infect Dis       Date:  2010-11-15       Impact factor: 9.079

3.  Therapeutic combination of radiofrequency surgical dissection and oral acitretin in the management of perianal Buschke-Lowenstein tumour: a case report.

Authors:  P Mavrogianni; E Fallidas; E Nicolaidou; K Villias; I Stefanaki; A Katsambas; T Lira; P Apostolopoulos; I Androne; G Rouvas; P Tsibouris; G Alexandrakis
Journal:  Int J STD AIDS       Date:  2012-05       Impact factor: 1.359

Review 4.  Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia.

Authors:  Peter Hillemanns; Mark H Einstein; Ole Erik Iversen
Journal:  Expert Opin Investig Drugs       Date:  2014-12-16       Impact factor: 6.206

Review 5.  Giant condyloma acuminatum (Buschke-Lowenstein tumor) of the anorectal and perianal regions. Analysis of 42 cases.

Authors:  Q D Chu; M P Vezeridis; N P Libbey; H J Wanebo
Journal:  Dis Colon Rectum       Date:  1994-09       Impact factor: 4.585
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.